RxDoctor Payments Data

Robert Comer, MD

Infectious Disease · Newport News, VANPI 1205056041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 26.2% of the total. Reporting peaked in 2023 at $492 and has fallen 54.0% since, to $226 in 2025.

$2,386in general payments, 2019–2025

Across 130 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$625
  • Gilead$546
  • Insmed, Inc.$340
  • AbbVie$214
  • Merck$163
  • Johnson & Johnson$109
  • plus $390 from 10 others

What the payments were for

  • Food & beverage$2,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,386 in reported general payments places this provider in the 80th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$26,152
Medicare patients
111
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala295$1,277,715
GenvoyaElviteg/Cob/Emtri/Tenof Alafen124$509,140
TriumeqAbacavir/Dolutegravir/Lamivudi63$242,583
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf43$224,929
OdefseyEmtricitab/Rilpiviri/Tenof Ala41$158,633
TivicayDolutegravir Sodium47$108,469
DovatoDolutegravir Sodium/Lamivudine28$82,583
DescovyEmtricitabine/Tenofov Alafenam33$71,631
PrezcobixDarunavir/Cobicistat27$70,239
JulucaDolutegravir/Rilpivirine16$65,162
Darunavir18$29,262
Daptomycin17$8,476
Rifabutin14$3,961
Ampicillin Sodium11$2,836
Vancomycin Hcl14$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$546$1,858,486452 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca$625$498,796154 claims
Johnson & JohnsonPrezcobix$109$70,23927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →